Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-03-04-02 Anti-androgens
| Cyproterone Acetate |
|
Formulary
|
Tablets 50mg, 100mg See section 06.04.02 for non-oncology indications. |
 MHRA: Cyproterone acetate: new advice to minimise risk of meningioma MHRA: High-dose cyproterone acetate: potential risk of (multiple) meningiomas |
|
| Goserelin |
|
Formulary
|
Implant 3.6mg (Zoladex®) See section 06.07.02 for non-oncology indications. |
|
|
| Leuprorelin Acetate |
|
Formulary
|
Injection 11.25mg (Prostap® 3) See section 06.07.02 for non-oncology indications. |
|
|
| Triptorelin Decapeptyl® SR |
|
Formulary
|
3-mg vial, 11.25-mg vial, 22.5-mg vial See section 06.07.02 for non-oncology indications. |
|
|
Links
- LSC Breast Chemotherapy Protocols
LSCMMG: Degarelix prescribing information sheet- MHRA Drug Safety Update Dec 2018: Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures
- MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA Drug Safety Update Sept 2018: Xofigo (radium-223-dichloride): new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial
- MHRA Drug Safety Update:High-dose cyproterone acetate: potential risk of (multiple) meningiomas
- MHRA: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA: High-dose cyproterone acetate: potential risk of (multiple) meningiomas
- NHSE: National Cancer Drugs Fund list
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG131: Prostate cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA316: Enzalutamide for prostate cancer
- NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
- NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
- NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
- NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
- NICE TA546: Padeliporfin for untreated localised prostate cancer (not recommended)
- NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
- NICE TA660:Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
- NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
- NICE TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
- NICE TA740:Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
- NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
- NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
- NICE TA995: Relugolix for treating hormone-sensitive prostate cancer
- TA259: Abiraterone for castration resistant prostate cancer
- TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated